Journal of Translational Medicine,
Год журнала:
2024,
Номер
22(1)
Опубликована: Май 30, 2024
Abstract
Background
Circular
RNAs
(circRNAs),
which
are
a
new
type
of
single-stranded
circular
RNA,
have
significant
involvement
in
progression
many
diseases,
including
tumors.
Currently,
multiple
circRNAs
been
identified
hepatocellular
carcinoma
(HCC).
Our
study
aims
to
investigate
the
function
and
mechanism
circDCAF8
HCC.
Methods
The
expression
(hsa_circ_0014879)
HCC
para-carcinoma
tissue
samples
was
determined
using
quantitative
real-time
polymerase
chain
reaction
(qRT-PCR).
biological
confirmed
by
experiments
conducted
both
vitro
vivo.
And
relationship
between
circDCAF8,
miR-217
NAP1L1
predicted
database
verified
qRT-PCR,
RNA-binding
protein
immunoprecipitation
(RIP)
dual-luciferase
reporter
assays.
Exosomes
isolated
from
cells
were
utilized
assess
connection
exosomal
with
angiogenesis
regorafenib
resistance.
Results
CircDCAF8
is
upregulated
tissues
cell
lines,
linked
an
unfavourable
prognosis
for
patients.
Functionally,
proved
facilitate
proliferation,
migration,
invasion
Epithelial-Mesenchymal
Transformation
(EMT)
cells.
Animal
examinations
also
validated
tumor-promoting
characteristics
on
Besides,
promoted
HUVECs.
Mechanistically,
interacted
downstream
miR-217.
sponging
In
addition,
exosomes
may
transfer
regorafenib-resistant
sensitive
cells,
where
it
would
confer
resistant
phenotype.
Conclusion
facilitates
proliferation
metastasis
via
miR-217/NAP1L1
axis.
Meanwhile,
can
promote
drive
resistance
regorafenib,
making
viable
therapeutic
target
Cells,
Год журнала:
2025,
Номер
14(2), С. 102 - 102
Опубликована: Янв. 11, 2025
Rheumatoid
arthritis
(RA)
is
a
chronic
autoimmune
disease
characterized
by
inflammation
leading
to
joint
damage
and
systemic
complications.
Angiogenesis
promotes
contributes
RA
progression.
This
study
evaluated
potential
anti-angiogenic
effects
of
several
compounds
including
small-molecule
kinase
inhibitors,
such
as
sunitinib
(pan-kinase
inhibitor),
tofacitinib
(JAK-inhibitor),
NIKi
(NF-κB-inducing
the
integrin-targeting
peptide
fluciclatide,
using
scratch
assay
3D
spheroid-based
models
angiogenesis.
For
all
drugs
tested
in
low
micromolar
range
(1–25
μM),
(as
positive
anti-angiogenetic
control)
showed
marked
inhibition
endothelial
cell
(EC)
migration
sprouting,
effectively
reducing
both
closure
sprout
formation.
Tofacitinib
exhibited
marginal
effectiveness
assay,
but
performed
better
(55%
inhibition),
whereas
around
50%
models.
Fluciclatide
changed
EC
morphology
rather
than
migration,
only
when
stimulated
with
synovial
fluid
spheroid
model
did
it
show
inhibitory
(at
≥2.5
µM),
none
below
this
dosage.
These
results
highlight
for
angiogenesis
fluciclatide
safe
diagnostic
targeting
microdose
RA,
well
need
advanced
screening
that
mimic
RA’s
complex
inflammatory
pro-angiogenic
environment.
